Metal complexes bearing EGFR‐inhibiting ligands as promising anticancer agents
Medicinal Research Reviews · 2024-07 · 44 (4) · 1545-1565
DOI: 10.1002/med.22021 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medicinal Research Reviews, online erschienen am 27.01.2024. Verfasst von Xiaoyan Ma und 4 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, School of Medicine, Nanjing University of Chinese Medicine,…. Hauptthemen laut MEDLINE: ErbB Receptors, Antineoplastic Agents, Protein Kinase Inhibitors, Coordination Complexes. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 62 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Overexpression of the epidermal growth factor receptor (EGFR, erbB1) has been observed in a wide range of solid tumors and has frequently been associated with poor prognosis. As a result, EGFR inhibition has become an attractive anticancer drug design strategy, and a large number of small molecular inhibitors have been developed. Despite the widespread clinical use of EGFR tyrosine kinase inhibitors (TKIs), their drug resistance, inadequate accumulation in tumors, and severe side effects have spurred the search for better antitumor drugs. Metal complexes have attracted much attention because of their different mechanisms compared with EGFR‐TKIs. Therefore, the combination of metals and inhibitors is a promising anticancer strategy. For example, Ru and Pt centers are introduced to design complexes with double or multiple targets, while Au complexes are combined with inhibitors to overcome drug resistance. Co complexes are designed as prodrugs with weak side effects and enhanced targeting by the hypoxia activation strategy, and other metals such as Rh and Fe enhance the anticancer effect of the complexes. In addition, the introduction of Ga center is beneficial to the development of nuclear imaging tracers. In this paper, metal EGFR‐TKI complexes in the last 15 years are reviewed, their mechanisms are briefly introduced, and their advantages are summarized.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, School of Medicine, Nanjing University of Chinese Medicine, Nanjing, People's Republic of China.
- State Key Laboratory of Coordination Chemistry, Nanjing University, Nanjing, People's Republic of China.
ORCID-Profile: Wukun Liu
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Ma, X., Wang, Z., Li, Y., Wang, Y., & Liu, W. (2024). Metal complexes bearing EGFR‐inhibiting ligands as promising anticancer agents. Medicinal Research Reviews, 44(4), 1545-1565. https://doi.org/10.1002/med.22021
Vancouver
Ma X, Wang Z, Li Y, Wang Y, Liu W. Metal complexes bearing EGFR‐inhibiting ligands as promising anticancer agents. Medicinal Research Reviews. 2024;44(4):1545-1565. doi:10.1002/med.22021
BibTeX
@article{Ma2024,
author = {Ma, Xiaoyan and Wang, Zhaoran and Li, Yifei and Wang, Yawen and Liu, Wukun},
title = {Metal complexes bearing EGFR‐inhibiting ligands as promising anticancer agents},
journal = {Medicinal Research Reviews},
year = {2024},
volume = {44},
number = {4},
pages = {1545--1565},
doi = {10.1002/med.22021}
}
EUVIMED